In short. What a test spot shows, how long it is watched before the rest of the face is treated, and why its result changes the plan rather than confirming it.
Key points
- The response that matters develops over weeks, not hours.
- Pigment that is going to darken after an injury does so as the skin settles and the inflammatory response resolves, so a test spot judged on the following day has not been given the chance to show anything.
- Treating the full face before that interval has passed removes the protection the test was performed to provide.
A test spot is the single most useful protective step in melasma treatment, and it is the step most often skipped when a course is sold as a package.
What it is
A small area of affected skin is treated using the same technique and settings that would be used for the full treatment, and it is then observed. Nothing else is treated until that observation is complete. The area is chosen so that an unfavourable response is small, visible and manageable, and so that it can be compared against the surrounding untreated skin.
The purpose is not to check whether the treatment works in general. It is to check how this skin responds to this treatment, which is the thing that cannot be predicted from appearance, from a previous patient's experience, or from the device and the agent involved.
Why the waiting period is the point
The response that matters develops over weeks, not hours. Pigment that is going to darken after an injury does so as the skin settles and the inflammatory response resolves, so a test spot judged on the following day has not been given the chance to show anything. Treating the full face before that interval has passed removes the protection the test was performed to provide.
What the result changes
A test spot that lightens without provoking inflammation supports proceeding, at the same settings and with the same spacing. A test spot that darkens, blisters, or leaves the skin reactive supports changing the plan: lower settings, a different agent, longer intervals, or abandoning the procedural route in favour of topical treatment and protection alone. A test spot that produces no change at all is also informative, because it suggests the pigment is not sitting where that treatment reaches.
That is why a test spot is a decision point rather than a formality. A clinic that performs one and then proceeds exactly as planned regardless of the result has performed the step without using it.
Reasons to insist on a test spot
- Melasma has already darkened after treatment before. The skin has shown how it responds.
- Your skin type is one in which pigmentary change is a common response to injury.
- The plan involves treating a large area, where an unfavourable response would affect a great deal of skin.
The test spot also produces a record. Photographs taken before and after it, kept alongside the note of the settings used, give the next appointment something to compare against. Without that record, a change in either direction is a matter of impression, and impressions are unreliable when the change being looked for is a gradual shift in colour over weeks.
Ask whether a test spot will be used, where it will be placed, and how long it will be watched before the rest of the face is treated. The answer tells you whether the plan is built around your skin or around a course of appointments.
Frequently asked questions
What is a test spot and what does it involve?
A small area of the affected skin is treated first, using the same technique and settings that would be used on the face, and it is then watched for a period before anything further is done. It shows how this skin responds to that specific energy or agent, in a place small enough that an unfavourable response is limited.
How long is a test spot watched?
Long enough for the skin to settle and for the pigment response to become visible, which is a matter of weeks rather than days. That waiting period is the point of the test rather than an inconvenience: a reaction that is going to darken the skin does so over that interval, and treating the whole face before it appears removes the protection the test provided.
What if the test spot darkens instead of lightening?
Then the plan changes. It may mean different settings, a different agent, a different interval, or no procedure at all. A test spot that darkens is a useful result, because it has shown the skin's response on a small area rather than across the whole face. It is not a failure of the test; it is the test doing its job.
Risks & Limitations
- Rebound darkening. Melasma-prone skin produces more pigment in response to inflammation, and both a laser and a peel create inflammation deliberately.
- Blistering, crusting or a burn if the settings or the contact time do not match the skin, with a small risk of scarring.
- Post-inflammatory pigment change in either direction, darker in most cases and lighter in some.
- Infection in skin that has been broken, and uneven peeling after a chemical agent.
- An allergic reaction to the peeling agent, which is a reason a test spot comes first.
- Increased sun sensitivity after either route, while the skin is settling and afterwards.
- Melasma is a tendency, not a lesion. Neither route removes it, both are followed by maintenance, and the pigment usually returns.
- No outcome is guaranteed, and individual response varies with the depth of the pigment, the skin type and how consistently the skin is protected.
When to Seek Care
- Blistering, crusting or a burn in the treated area — contact the treating team the same day.
- The treated area becoming darker rather than lighter after a session has settled.
- Spreading redness, swelling, pain or discharge, or a fever.
- Skin that stays red, stings or feels reactive between sessions rather than returning to normal.
- A dark patch that is new, changing in size, shape or colour, bleeding or failing to heal — seek assessment rather than treatment.
- Difficulty breathing, or swelling of the lips, tongue or throat after a chemical peel — seek emergency care immediately.
References & Further Reading
- American Academy of Dermatology Association (AAD) — patient information on melasma and pigmentary disorders
- British Association of Dermatologists (BAD) — guidance on laser and light therapy and on chemical peels
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance on skin lesions and referral
- Cochrane Library — systematic reviews in the treatment of melasma
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.